RxDoctor Payments Data

Edgardo Osea, MD

Internal Medicine · Carson, CANPI 1699795476

Payments from drug & device makers

$215,682in general payments, 2019–2025

Across 128 payments — averaging $1685.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$214K
  • AstraZeneca$1K
  • Novo Nordisk$259
  • Amarin Pharma, Inc.$129
  • Merck$81
  • Johnson & Johnson$72
  • plus $184 from 5 others

What the payments were for

  • Food & beverage$2,038100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer52$213,659
AstraZeneca39$1,297
Novo Nordisk17$259
Amarin Pharma, Inc.2$129
Merck4$81
Johnson & Johnson(2 entities)4$72
Abbott3$68
AbbVie(2 entities)3$48
Almatica Pharma LLC2$32
Mannkind Corporation1$20
Dexcom, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$215,682 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$42,913
Medicare patients
115
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol213$248,501
JanuviaSitagliptin Phosphate92$125,624
LinzessLinaclotide79$83,586
OzempicSemaglutide60$66,675
MounjaroTirzepatide47$63,825
EliquisApixaban59$48,974
TrulicityDulaglutide42$45,523
JardianceEmpagliflozin35$40,515
RybelsusSemaglutide24$37,716
XareltoRivaroxaban18$27,377
TradjentaLinagliptin11$15,765
JanumetSitagliptin Phos/Metformin Hcl16$13,070
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,616
Atorvastatin Calcium846$9,025
DapagliflozinDapagliflozin Propanediol17$8,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,297$261,117226 claims
MerckJanuvia, Janumet$81$138,694108 claims
Novo NordiskOzempic, Rybelsus$259$104,39184 claims
AbbVieLinzess$48$83,58679 claims
PfizerEliquis, Dilantin$213,659$50,86870 claims
Johnson & JohnsonXarelto$72$27,37718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Carson

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →